Receive your daily health and medicine insights every weekday with STAT’s complimentary newsletter, Morning Rounds. Join here.
October has arrived, bringing the perfect opportunity to enjoy hot apple cider while indulging in episodes of Over the Garden Wall. How about some Potatoes and Molasses?
NIH’s $50 Million Autism Initiative
Recently, the National Institutes of Health revealed the 13 research teams that will be funded to explore autism. This research spans various approaches, yet a notable trend is emerging: the federal government is intensifying focus on environmental factors to understand autism development.
There’s a growing awareness among scientists that environmental influences during pregnancy may play a role in autism diagnoses, despite the prevailing belief that the disorder is primarily genetic. This area of study is referred to as the exposome, a term that captures the vast range of environmental factors one is exposed to.
For more details on the exposome and the initiatives receiving funding, check out my article. Here’s an insightful comment from autism researcher Craig Newschaffer regarding the challenges of assessing environmental exposures.
“DNA, RNA, protein—we understand those concepts. But when it comes to the exposome, what exactly are we measuring?” said Newschaffer, who did not apply for the NIH funding. “Humans don’t encounter just one exposure; we’re surrounded by a plethora of influences in our natural environment.”
NIH’s Shift Away from Animal Research
Introducing Nicole Kleinstreuer, the driving force behind the NIH’s initiative to minimize animal usage in biomedical studies.
As the acting deputy director for program coordination, planning, and strategic initiatives, she has been instrumental in the NIH’s recent announcement of an $87 million initiative to promote innovative methodologies, specifically organoids—miniature cell cultures that simulate human organs. A self-proclaimed math enthusiast, Kleinstreuer is also pioneering efforts for new non-animal research strategies.
Interested in Kleinstreuer’s insights on which scientific areas might find it challenging to identify non-animal alternatives? Or curious about how organoids are engaging in gaming? Discover more here.
Controversy Surrounding FDA’s Approval of Generic Mifepristone
The routine approval process for generic medications at the FDA attracted scrutiny on Thursday following the approval of a new generic form of the abortion pill mifepristone by federal authorities.
Evita Solutions announced on its site that the FDA endorsed its cost-effective version of the pill, approved for terminating pregnancies up to 10 weeks. This regulatory approval sparked backlash from anti-abortion advocates and politicians supportive of the Trump administration. High-ranking health officials are under increasing pressure from abortion opposition groups to reconsider the status of mifepristone, which has been recognized as safe and effective by FDA scientists since its approval 25 years ago.
Generally, the FDA processes such applications within a 10-month window. However, documents available on the FDA’s website indicate that Evita Solutions submitted their application four years prior. Learn more here.
Trump Administration Delays Drug Price Negotiation Proposal
President Trump has consistently urged pharmaceutical companies to decrease their prices for American consumers. However, the administration is now postponing a proposal aimed at closing a loophole that enables drugmakers to sidestep Medicare price negotiations, as reported by STAT’s John Wilkerson.
Earlier this year, the administration aimed to address a loophole in the drug price negotiation system that allows companies to avoid negotiations through ingredient pairing. This guideline was set to impact drugs in the near future.
Yet, the newly released guidance indicates that the Centers for Medicare and Medicaid Services will defer implementing this policy for an additional year. This choice exemplifies the administration’s leniency towards drug manufacturers, even as President Trump publicly demands action from them. Read more from John here.
Eugenic Rhetoric Revived by Trump Administration’s Autism Discourse
Robert F. Kennedy Jr., the health secretary, has referred to autism as an epidemic requiring urgent intervention, a characterization that is misleading, asserts Shoumita Dasgupta, a professor at Boston University Chobanian & Avedisian School of Medicine. This perspective not only misrepresents facts but also dehumanizes individuals with autism, reminiscent of early 20th-century eugenics.
Dasgupta states, “The Trump administration is rekindling eugenic ideologies” through measures like restricting acetaminophen use during pregnancy, withholding vaccines from children, and searching for genetic factors associated with autism.
She adds, “This problematic depiction of autistic individuals as issues to be resolved adopts a narrow view of autism and related identities, concentrating solely on perceived deficits.” Explore more about the historical parallels in contemporary discussions here.
Our Reading Recommendations
-
Exclusive: Former CDC Director Discusses Her Dismissal, Nature
- Is the rise in cancer among younger adults an illusion? Vox
- Efforts to Improve Prostate Cancer Treatment, Bloomberg
- Workers’ Income Redirected for Healthcare Expenses Despite Consumer Protections, KFF Health News
- Trump Addresses Health and Tech Giants: AI Isn’t Your ‘Cartel’, Politico
